Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Biologics
Effectiveness
Health outcomes
Interleukin
Ixekizumab
Psoriasis
Real-world evidence
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
received:
09
11
2023
accepted:
08
12
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
Given the chronic nature of psoriasis (PsO), more studies are needed that directly compare the effectiveness of different biologics over long observation periods. This study compares the effectiveness and durability through 12 months of anti-interleukin (IL)-17A biologics relative to other approved biologics in patients with moderate-to-severe psoriasis in a real-world setting. The Psoriasis Study of Health Outcomes (PSoHO) is an ongoing 3-year, prospective, non-interventional cohort study of 1981 adults with chronic moderate-to-severe plaque psoriasis initiating or switching to a new biologic. The study compares the effectiveness of anti-IL-17A biologics with other approved biologics and provides pairwise comparisons of seven individual biologics versus ixekizumab. The primary outcome was defined as the proportion of patients who had at least a 90% improvement in Psoriasis Area and Severity Index score (PASI90) and/or a score of 0 or 1 in static Physician Global Assessment (sPGA). Secondary objective comparisons included the proportion of patients who achieved PASI90, PASI100, a Dermatology Life Quality Index (DLQI) score of 0 or 1, and three different actions of durability of treatment response. Unadjusted response rates are presented alongside the primary analysis, which uses frequentist model averaging (FMA) to evaluate the adjusted comparative effectiveness. Compared to the other biologics cohort, the anti-IL-17A cohort had a higher response rate (68.0% vs. 65.1%) and significantly higher odds of achieving the primary outcome at month 12. The two cohorts had similar response rates for PASI100 (40.5% and 37.1%) and PASI90 (53.9% and 51.7%) at month 12, with no significant differences between the cohorts in the adjusted analyses. At month 12, the response rates across the individual biologics were 53.5-72.6% for the primary outcome, 27.6-48.3% for PASI100, and 41.7-61.4% for PASI90. These results show the comparative effectiveness of biologics at 6 and 12 months in the real-world setting. ClinicalTrials.gov identifier EUPAS24207.
Identifiants
pubmed: 38113010
doi: 10.1007/s13555-023-01086-9
pii: 10.1007/s13555-023-01086-9
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2023. The Author(s).
Références
Curmin R, Guillo S, De Rycke Y, et al. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2022;36:2101–12.
doi: 10.1111/jdv.18409
pubmed: 35793473
pmcid: 9796114
Dave R, Alkeswani A. An overview of biologics for psoriasis. J Drugs Dermatol. 2021;20:1246–7.
doi: 10.36849/JDD.6040
pubmed: 34784122
Augustin M, Schuster C, Mert C, et al. The value of indirect comparisons of systemic biologics for psoriasis: interpretation of efficacy findings. Dermatol Ther (Heidelb). 2022;12:1711–27.
doi: 10.1007/s13555-022-00765-3
pubmed: 35834062
Nast A, Dressler C, Schuster C, et al. Methods used for indirect comparisons of systemic treatments for psoriasis. A systematic review. Skin Health Dis. 2023;3:e112.
doi: 10.1002/ski2.112
pubmed: 36751312
Lynde C, Riedl E, Maul J-T, et al. Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at week 12 from the PSoHO study in a real-world setting. Adv Ther. 2023;40(3):869–86.
Pinter A, Puig L, Schäkel K, et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022;36(11):2087–2100.
European Medicines Agency. Psoriasis Study of Health Outcomes—an international observational study of 3 year health outcomes in the biologic treatment of moderate to severe plaque psoriasis. ENCePP. https://www.encepp.eu/encepp/viewResource.htm?id=25115 . EUPAS24207. 2018.
Tada Y, Watanabe R, Noma H, et al. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Dermatol Sci. 2020;99:53–61.
doi: 10.1016/j.jdermsci.2020.06.003
pubmed: 32600737
Reich A, Pinter A, Maul JT, et al. Speed of clinical improvement in the real-world setting from patient-reported psoriasis symptoms and signs diary (PSSD): secondary outcomes from the psoriasis study of health outcomes (PSoHO) through 12 weeks. J Eur Acad Dermatol Venereol. 2023;37(9):1825–40.
Warren RB, See K, Burge R, et al. Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network meta-analyses. Dermatol Ther. 2020;10:73–86.
doi: 10.1007/s13555-019-00337-y
Yasmeen N, Sawyer LM, Malottki K, et al. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J Dermatol Treat. 2022;33:204–18.
doi: 10.1080/09546634.2020.1743811
Armstrong A, Fahrbach K, Leonardi C, et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther. 2022;12:1777–92.
doi: 10.1007/s13555-022-00760-8
Nordon C, Karcher H, Groenwold RH, et al. The “efficacy-effectiveness gap”: historical background and current conceptualization. Value Health. 2016;19:75–81.
doi: 10.1016/j.jval.2015.09.2938
pubmed: 26797239
Garcia-Doval I, Carretero G, Vanaclocha F, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012;148:463–70.
doi: 10.1001/archdermatol.2011.2768
pubmed: 22508869
Mason KJ, Barker JN, Smith CH, et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol. 2018;154:581–8.
doi: 10.1001/jamadermatol.2018.0183
pubmed: 29590279
pmcid: 5876819
Augustin M, Valencia López M, Reich K. Network meta-analyses in psoriasis: overview and critical discussion. J Eur Acad Dermatol Venereol. 2021;35:2367–76.
doi: 10.1111/jdv.17650
pubmed: 34506643
Blauvelt A, Papp K, Gottlieb A, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182:1348–58.
doi: 10.1111/bjd.18851
pubmed: 31887225
pmcid: 7317420
Megna M, Potestio L, Camela E, et al. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35:e15667.
doi: 10.1111/dth.15667
pubmed: 35762107
pmcid: 9540270
Papp K, Paul C, Kleyn CE, et al. Time to loss of response following withdrawal of ixekizumab in patients with moderate-to-severe psoriasis. Acta Dermato-Venereol. 2022;102:adv00672-adv.
Daniele S, Eldirany SA, Ho M, et al. Structural basis for differential p19 targeting by IL-23 biologics. bioRxiv 2023:2023.03.09.531913.
Eldirany SA, Ho M, Bunick CG. Focus: skin: structural basis for how biologic medicines bind their targets in psoriasis therapy. Yale J Biol Med. 2020;93:19.
pubmed: 32226331
pmcid: 7087057
Blauvelt A, Gooderham M, Griffiths CEM, et al. Cumulative clinical benefits of biologics in the treatment of patients with moderate-to-severe psoriasis over 1 year: a network meta-analysis. Dermatol Ther (Heidelb). 2022;12:727–40.
doi: 10.1007/s13555-022-00690-5
pubmed: 35195887
Gargiulo L, Ibba L, Malagoli P, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study-IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2023;37(5):1017–27.
Mastorino L, Susca S, Cariti C, et al. “Superresponders” at biologic treatment for psoriasis: a comparative study among IL17 and Il23 inhibitors. Exp Dermatol. 2023;32(12):2187–88.
Di Cesare A, Ricceri F, Rosi E, et al. Therapy of PsO in special subsets of patients. Biomedicines. 2022;10:2879.
doi: 10.3390/biomedicines10112879
pubmed: 36359399
pmcid: 9687729
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80:43–53.
doi: 10.1016/j.jaad.2018.06.056
pubmed: 30017706
Piaserico S, Riedl E, Pavlovsky L, et al. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO). Front Med (Lausanne). 2023;10;1185523.